- Home
- CRDF vs LEGT Comparison
CRDF vs LEGT Comparison
Compare CRDF & LEGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- LEGT
- Stock Information
- Founded
- CRDF 1999
- LEGT 2023
- Country
- CRDF United States
- LEGT United States
- Employees
- CRDF N/A
- LEGT N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- LEGT
- Sector
- CRDF Health Care
- LEGT
- Exchange
- CRDF Nasdaq
- LEGT Nasdaq
- Market Cap
- CRDF 288.7M
- LEGT 269.6M
- IPO Year
- CRDF N/A
- LEGT 2024
- Fundamental
- Price
- CRDF $3.83
- LEGT $10.45
- Analyst Decision
- CRDF Strong Buy
- LEGT
- Analyst Count
- CRDF 4
- LEGT 0
- Target Price
- CRDF $12.00
- LEGT N/A
- AVG Volume (30 Days)
- CRDF 1.1M
- LEGT 14.4K
- Earning Date
- CRDF 05-01-2025
- LEGT 01-01-0001
- Dividend Yield
- CRDF N/A
- LEGT N/A
- EPS Growth
- CRDF N/A
- LEGT N/A
- EPS
- CRDF N/A
- LEGT 0.32
- Revenue
- CRDF $683,000.00
- LEGT N/A
- Revenue This Year
- CRDF N/A
- LEGT N/A
- Revenue Next Year
- CRDF N/A
- LEGT N/A
- P/E Ratio
- CRDF N/A
- LEGT $0.66
- Revenue Growth
- CRDF 39.96
- LEGT N/A
- 52 Week Low
- CRDF $2.01
- LEGT $10.00
- 52 Week High
- CRDF $6.42
- LEGT $10.47
- Technical
- Relative Strength Index (RSI)
- CRDF 43.91
- LEGT N/A
- Support Level
- CRDF $3.52
- LEGT N/A
- Resistance Level
- CRDF $4.42
- LEGT N/A
- Average True Range (ATR)
- CRDF 0.29
- LEGT 0.00
- MACD
- CRDF -0.04
- LEGT 0.00
- Stochastic Oscillator
- CRDF 18.89
- LEGT 0.00
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.